Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Hold” from Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has received an average recommendation of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat reports. Nine analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company.

Several equities research analysts recently commented on ZLDPF shares. Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, September 11th. Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Barclays cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th.

Zealand Pharma A/S Trading Down 2.6%

Shares of OTCMKTS:ZLDPF opened at $41.99 on Friday. The company has a 50 day moving average of $47.12 and a 200-day moving average of $46.32. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a market cap of $3.00 billion, a P/E ratio of 6.96 and a beta of 0.89. Zealand Pharma A/S has a twelve month low of $35.93 and a twelve month high of $83.12.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes.